Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and cancer, has announced a strategic research collaboration with SRL Inc., a premier Japanese healthcare service provider. This partnership is designed to enhance the distribution of Vela Diagnostics’ advanced molecular diagnostic solutions within Japan, although financial details of the agreement remain undisclosed.
Significance of the Collaboration
The research collaboration agreement (RCA) between Vela Diagnostics and SRL was officially signed in June 2023, representing a significant milestone in their mutual commitment to advancing healthcare solutions in the Japanese market. Through this partnership, Vela aims to leverage SRL, Inc.’s extensive distribution network and deep market insights to introduce its Sentosa SQ HIV-1 Genotyping Assay Kit to healthcare and diagnostic institutions across Japan.
Innovative Diagnostic Solutions
Vela Diagnostics is recognized for its integrated in vitro diagnostic (IVD) system solutions, which streamline the testing process from sample collection to result delivery. The company’s test solutions utilize the automated Sentosa platform, offering a unique capability to perform next-generation sequencing (NGS) and PCR testing for both infectious diseases and oncology. Established in 1970, SRL, Inc. (a subsidiary of H.U. Group Holdings, Inc.) is a well-respected clinical laboratory testing company in Japan, boasting over 80 nationwide business locations. SRL specializes in complex testing, catering to prestigious clients and providing comprehensive diagnostic solutions for disease management, treatment planning, post-treatment monitoring, and health checkups.-Fineline Info & Tech
